VEMLIDY

Nazione: Indonesia

Lingua: indonesiano

Fonte: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Principio attivo:

TENOFOVIR ALAFENAMIDE FUMARATE

Commercializzato da:

SOHO INDUSTRI PHARMASI - Indonesia

INN (Nome Internazionale):

TENOFOVIR ALAFENAMIDE FUMARATE

Dosaggio:

28.04 MG

Forma farmaceutica:

TABLET SALUT SELAPUT

Confezione:

DUS, BOTOL @30 TABLET SALUT SELAPUT

Prodotto da:

Patheon inc - Canada

Data dell'autorizzazione:

2019-01-24

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF MEDICINAL PRODUCT
_1.1 _
_PRODUCT NAME _
Vemlidy™ 25 mg film-coated tablets.
_1.2. _
_STRENGTH _
Tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir
alafenamide.
_1.3 _
_PHARMACEUTICAL DOSAGE FORM _
Film-coated tablet.
2.
QUALITY AND QUANTITATIVE COMPOSITION
_2.1 _
_QUALITATIVE DECLARATION _
Tenofovir alafenamide fumarate
_2.2 _
_QUANTITATIVE DECLARATION_
Each film-coated tablet contains tenofovir alafenamide fumarate
equivalent to 25 mg of
tenofovir alafenamide.
3.
PHARMACEUTICAL FORM
Yellow, round, film-coated tablets,
8 mm in diameter, debossed with “GSI” on one side of the
tablet and “25” on the other side of the tablet.
4.
CLINICAL PARTICULARS
_4.1 _
_THERAPEUTIC INDICATION _
Vemlidy is indicated for the treatment of chronic hepatitis B in
adults.
_4.2. _
_POSOLOGY AND METHOD OF ADMINISTRATION _
Therapy should be initiated by a physician experienced in the
management of chronic
hepatitis B.
Posology
Adults: one tablet once daily.
_Treatment discontinuation _
Treatment discontinuation may be considered as follows:

In HBeAg-positive patients without cirrhosis, treatment should be
administered for at
least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA
loss with
anti-HBe detection) is confirmed or until HBs seroconversion or until
there is loss of
efficacy. Regular reassessment is recommended after treatment
discontinuation to
detect virological relapse.

In HBeAg-negative patients without cirrhosis, treatment should be
administered at least
until HBs seroconversion or until there is evidence of loss of
efficacy. With prolonged
treatment for more than 2 years, regular reassessment is recommended
to confirm that
continuing the selected therapy remains appropriate for the patient.
_Missed dose _
If a dose is missed and less than 18 hours have passed from the time
it is usually taken, the
patient should take Vemlidy as soon as possible and then resume their
normal dosing
schedule. If more than 18 hours have passed from the tim